Grifols, S.A.
GRF
Rang in Aktien
#2401
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Aktienkurs
$12.03
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$8.19B
Veränderung (1 Tag)
0.50%
Veränderung (1 Jahr)
75.59%
Land
ES
Handel Grifols, S.A. (GRF)
Kategorie
Healthcare
Marktkapitalisierung von Grifols, S.A.(GRF)
Marktkapitalisierung: $8.19B
Mit Stand October 2026 hat Grifols, S.A. eine Marktkapitalisierung von $8.19B. Das macht Grifols, S.A. laut unseren Daten zum 2401st wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Grifols, S.A. von 2009 bis 2026
GRF im Vergleich zu den Top 5 der beliebtesten stocks
